Pipeline
A Pipeline Built on Novel Retinal Pathways
| Program | Therapeutic Approach | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Commercial Rights |
|---|---|---|---|---|---|---|---|---|
| Diseases of Retinal Ischemia | ||||||||
| KIO-401 | Calpain Inhibitor | CRAO Commercial rights: Global Rights (outside Asia) | Global Rights (outside Asia) |
|||||
| NAION Commercial rights: Global Rights (outside Asia) | ||||||||
| Inherited Retinal Disease | ||||||||
| KIO-301 | Molecular Photoswitch |
Retinitis Pigmentosa (advanced) Commercial rights: Partnered Globally |
Partnered Globally |
|||||
|
Other Inherited Retinal Diseases Commercial rights: Partnered Globally |
||||||||
KIO-401 received Orphan Drug Designation (USA) for CRAO.
KIO-301 received Orphan Drug Designation (USA – March 2022) and Orphan Medicinal Product Designation (EU – July 2024).